Director/PDMR Shareholding

RNS Number : 2974J

Epistem Holdings plc

16 December 2015

 

Epistem Holdings Plc ("Epistem" or the "Company")

For release: 16 December 2015

Director/PDMR Shareholding

Epistem Holdings Plc (LSE: EHP) ("Epistem" or "the Company"), the personalised medicine and biotechnology company, announces that it has today been notified that the Company's Chairman and Interim Chief Executive Officer, Dr. Ian Gilham, today has acquired 20,500 ordinary shares in the Company at a price of 120p, the Company's Finance Director, John Rylands, today has acquired 20,749 ordinary shares in the Company at a price of 120p and the Company's Chief Operating Officer, Dr. Allan Brown, today has acquired 20,749 ordinary shares in the Company at a price of 120p.

Following this transaction, Dr. Ian Gilham has a beneficial holding of 20,500 ordinary shares in the Company, representing approximately 0.19% of the issued share capital of the Company, John Rylands has a beneficial holding of 218,773 ordinary shares in the Company, representing approximately 2.07% of the issued share capital of the Company and Dr. Allan Brown has a beneficial holding of 23,461 ordinary shares in the Company, representing approximately 0.22% of the issued share capital of the Company.

On 15 December 2015 the Remuneration Committee agreed to a two year extension until 10 January 2018 in respect of 226,708 share options exercisable at 120p per share held by Finance Director, John Rylands, and Managing Director, Catherine Booth, which were issued on 10 January 2006 and are fully vested.

Together with other options, John Rylands holds fully vested options over a total of 211,180 ordinary shares of 1.5p, representing 2.00% of the current issued share capital of the Company and Catherine Booth holds fully vested options over a total of 15,528 ordinary shares of 1.5p, representing 0.15% of the current issued share capital of the Company.

For further details please contact:

Epistem Holdings Plc

Dr Ian Gilham: Chairman                                                                                       [phone]

John Rylands: Finance Director

Peel Hunt LLP

James Steel                                                                                                                [phone]

Tom Burt

Oliver Jackson

Consilium Strategic Communications

Chris Gardner / Laura Thornton                                                                          [phone]

[e-mail] 

Notes to Editors

Epistem is a personalised medicine and biotechnology company developing innovative diagnostics and biomarkers alongside providing contract research services to drug development companies. Genedrive® provides a major advance in molecular diagnostic testing by providing a rapid, low cost, simple to use 'Point of Care' device with high sensitivity and specificity for the diagnostics of infectious diseases and for use in patient stratification (genotyping). Genedrive® aims to provide a 'gold standard' identification of Tuberculosis & antibiotic resistance. The World Health Organisation (WHO) has publicly recommended that nations incorporate new rapid and molecular tests for Tuberculosis into their disease testing programs. The Genedrive® platform and its first Tuberculosis test is now being prepared for launch in India and the India sub-continent. Further details can be found at: www.epistem.co.uk and www.genedrive.com

 

END

 

 

RDSBSBDDSBBBGUL